SIGA
Price
$3.61
Change
+$0.02 (+0.56%)
Updated
Jul 13 closing price
Capitalization
258.92M
16 days until earnings call
Intraday BUY SELL Signals
XERS
Price
$8.16
Change
-$0.18 (-2.16%)
Updated
Jul 13 closing price
Capitalization
1.41B
23 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

SIGA vs XERS

SIGA vs XERS Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
SIGA vs. XERS commentary
Jul 14, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SIGA is a Hold and XERS is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 14, 2026
Stock price -- (SIGA: $3.61 vs. XERS: $8.16)
Brand notoriety: SIGA and XERS are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: SIGA: 68% vs. XERS: 51%
Market capitalization -- SIGA: $258.92M vs. XERS: $1.41B
SIGA [@Pharmaceuticals: Generic] is valued at $258.92M. XERS’s [@Pharmaceuticals: Generic] market capitalization is $1.41B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.97B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SIGA’s FA Score shows that 2 FA rating(s) are green whileXERS’s FA Score has 1 green FA rating(s).

  • SIGA’s FA Score: 2 green, 3 red.
  • XERS’s FA Score: 1 green, 4 red.
According to our system of comparison, XERS is a better buy in the long-term than SIGA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SIGA’s TA Score shows that 4 TA indicator(s) are bullish while XERS’s TA Score has 5 bullish TA indicator(s).

  • SIGA’s TA Score: 4 bullish, 5 bearish.
  • XERS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, XERS is a better buy in the short-term than SIGA.

Price Growth

SIGA (@Pharmaceuticals: Generic) experienced а -3.73% price change this week, while XERS (@Pharmaceuticals: Generic) price change was -2.51% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -3.88%. For the same industry, the average monthly price growth was +0.21%, and the average quarterly price growth was +13.40%.

Reported Earning Dates

SIGA is expected to report earnings on Jul 30, 2026.

XERS is expected to report earnings on Aug 06, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-3.88% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
XERS($1.41B) has a higher market cap than SIGA($259M). XERS has higher P/E ratio than SIGA: XERS (116.57) vs SIGA (12.89). XERS YTD gains are higher at: 3.949 vs. SIGA (-33.210). XERS has higher annual earnings (EBITDA): 53.4M vs. SIGA (21.2M). SIGA has more cash in the bank: 146M vs. XERS (112M). SIGA has less debt than XERS: SIGA (538K) vs XERS (259M). XERS has higher revenues than SIGA: XERS (315M) vs SIGA (93.8M).
SIGAXERSSIGA / XERS
Capitalization259M1.41B18%
EBITDA21.2M53.4M40%
Gain YTD-33.2103.949-841%
P/E Ratio12.89116.5711%
Revenue93.8M315M30%
Total Cash146M112M130%
Total Debt538K259M0%
FUNDAMENTALS RATINGS
SIGA vs XERS: Fundamental Ratings
SIGA
XERS
OUTLOOK RATING
1..100
6646
VALUATION
overvalued / fair valued / undervalued
1..100
1
Undervalued
87
Overvalued
PROFIT vs RISK RATING
1..100
10051
SMR RATING
1..100
68100
PRICE GROWTH RATING
1..100
8238
P/E GROWTH RATING
1..100
2830
SEASONALITY SCORE
1..100
n/a44

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SIGA's Valuation (1) in the Pharmaceuticals Other industry is significantly better than the same rating for XERS (87) in the Pharmaceuticals Major industry. This means that SIGA’s stock grew significantly faster than XERS’s over the last 12 months.

XERS's Profit vs Risk Rating (51) in the Pharmaceuticals Major industry is somewhat better than the same rating for SIGA (100) in the Pharmaceuticals Other industry. This means that XERS’s stock grew somewhat faster than SIGA’s over the last 12 months.

SIGA's SMR Rating (68) in the Pharmaceuticals Other industry is in the same range as XERS (100) in the Pharmaceuticals Major industry. This means that SIGA’s stock grew similarly to XERS’s over the last 12 months.

XERS's Price Growth Rating (38) in the Pharmaceuticals Major industry is somewhat better than the same rating for SIGA (82) in the Pharmaceuticals Other industry. This means that XERS’s stock grew somewhat faster than SIGA’s over the last 12 months.

SIGA's P/E Growth Rating (28) in the Pharmaceuticals Other industry is in the same range as XERS (30) in the Pharmaceuticals Major industry. This means that SIGA’s stock grew similarly to XERS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
SIGAXERS
RSI
ODDS (%)
Bullish Trend 1 day ago
88%
Bearish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
75%
Bullish Trend 4 days ago
89%
MACD
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
86%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
75%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 12 days ago
84%
Declines
ODDS (%)
Bearish Trend 5 days ago
73%
Bearish Trend 1 day ago
78%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
82%
Aroon
ODDS (%)
Bearish Trend 1 day ago
70%
Bullish Trend 1 day ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
SIGA
Daily Signal:
Gain/Loss:
XERS
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
FOREX / NAMEPrice $Chg $Chg %
CADUSD0.720.01
+1.89%
Canadian Dollar - United States Dollar
PPH108.80N/A
N/A
VanEck Pharmaceutical ETF
PSCU64.48N/A
N/A
Invesco S&P SmallCap Ult & Comnc Svc ETF
FINX25.61N/A
N/A
Global X FinTech ETF
DOJE6.65-0.22
-3.20%
REX-Osprey DOGE ETF